hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06284486, orgStudyIdInfo id: 2023-0794, secondaryIdInfos id: NCI-2024-01721, type: OTHER, domain: NCI-CTRP Clinical Registry, briefTitle: A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-07-31, primaryCompletionDateStruct date: 2026-12-30, completionDateStruct date: 2028-12-30, studyFirstPostDateStruct date: 2024-02-29, lastUpdatePostDateStruct date: 2024-03-27, sponsorCollaboratorsModule leadSponsor name: M.D. Anderson Cancer Center, class: OTHER, collaborators name: Syndax Pharmaceuticals, collaborators name: Break Through Cancer, collaborators name: AbbVie, descriptionModule briefSummary: To learn if the combination of venetoclax and revumenib can help to control MRD-positive AML., conditionsModule conditions: Acute Myeloid Leukemia, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 8, type: ESTIMATED, armsInterventionsModule interventions name: Venetoclax, interventions name: Revumenib, outcomesModule primaryOutcomes measure: Safety and adverse events (AEs), eligibilityModule sex: ALL, minimumAge: 12 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: MD Anderson Cancer Center, city: Houston, state: Texas, zip: 77030, country: United States, contacts name: Ghayas Issa, MD, role: CONTACT, phone: 713-745-6798, email: gcissa@mdanderson.org, contacts name: Ghayas Issa, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 29.76328, lon: -95.36327, hasResults: False
protocolSection identificationModule nctId: NCT06284460, orgStudyIdInfo id: 2022-0622, secondaryIdInfos id: NCI-2024-01692, type: OTHER, domain: NCI-CTRP Clinical Registry, briefTitle: Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-07-31, primaryCompletionDateStruct date: 2025-12-01, completionDateStruct date: 2027-12-01, studyFirstPostDateStruct date: 2024-02-29, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: M.D. Anderson Cancer Center, class: OTHER, descriptionModule briefSummary: The goal of Part 1 of this clinical research study is to find the highest tolerable dose of ASTX029 that can be given in combination with ASTX727 to participants who have RAS-mutant MDS or MDS/MPN. The goal of Part 2 of this clinical research study is to learn if the dose of ASTX029 found in Part 1 can help to control the disease when used in combination with ASTX727., conditionsModule conditions: Pathway Mutant Myelodysplastic Syndromes, conditions: Myelodysplastic Neoplasm, conditions: Myeloproliferative Neoplasm, designModule studyType: INTERVENTIONAL, phases: PHASE1, phases: PHASE2, designInfo allocation: NON_RANDOMIZED, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 36, type: ESTIMATED, armsInterventionsModule interventions name: ASTX029, interventions name: ASTX727, outcomesModule primaryOutcomes measure: Safety and adverse events (AEs), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: MD Anderson Cancer Cente, city: Houston, state: Texas, zip: 77030, country: United States, contacts name: Guillermo Montalban Bravo, MD, role: CONTACT, phone: 713-794-3604, email: gmontalban1@mdanderson.org, contacts name: Guillermo Montalban Bravo, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 29.76328, lon: -95.36327, hasResults: False
protocolSection identificationModule nctId: NCT06284447, orgStudyIdInfo id: 22-004500, secondaryIdInfos id: NCI-2024-00181, type: REGISTRY, domain: CTRP (Clinical Trial Reporting Program), secondaryIdInfos id: 22-004500, type: OTHER, domain: Mayo Clinic Institutional Review Board, briefTitle: Barriers to Cervical Cancer Screening, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-03-23, primaryCompletionDateStruct date: 2025-03-31, completionDateStruct date: 2025-03-31, studyFirstPostDateStruct date: 2024-02-29, lastUpdatePostDateStruct date: 2024-02-29, sponsorCollaboratorsModule leadSponsor name: Mayo Clinic, class: OTHER, descriptionModule briefSummary: This study evaluates barriers to cervical cancer screening among non-compliant women., conditionsModule conditions: Cervical Carcinoma, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 200000, type: ESTIMATED, armsInterventionsModule interventions name: Non-Interventional Study, outcomesModule primaryOutcomes measure: Identify barriers to cervical cancer screening, eligibilityModule sex: FEMALE, minimumAge: 21 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Mayo Clinic in Rochester, status: RECRUITING, city: Rochester, state: Minnesota, zip: 55905, country: United States, contacts name: Clinical Trials Referral Office, role: CONTACT, phone: 855-776-0015, email: mayocliniccancerstudies@mayo.edu, contacts name: Brittany A. Strelow, DSMc, PA-C, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 44.02163, lon: -92.4699, hasResults: False
protocolSection identificationModule nctId: NCT06284434, orgStudyIdInfo id: CHI2311, briefTitle: Liposomal Bupivacaine Use in Alveolar Bone Graft Patients, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2026-03, completionDateStruct date: 2026-03, studyFirstPostDateStruct date: 2024-02-29, lastUpdatePostDateStruct date: 2024-03-04, sponsorCollaboratorsModule leadSponsor name: Kerry O'Rourke, class: OTHER, collaborators name: Shriners Hospitals for Children, descriptionModule briefSummary: The goal of this clinical trial is to learn if a pain medication called liposomal bupivacaine (brand name EXPAREL®) with epinephrine will provide better pain control, increased activity, and reduced use of opioids compared with the standard treatment for patients age 6 years and older with cleft lip and palate who have had an alveolar bone graft surgery. Investigators will look at:* pain scores at hip and jaw sites* opioid use in amount and frequency* scores on activity questionnaires Researchers will compare the results of these items with those of patients who had the standard treatment of bupivacaine with epinephrine., conditionsModule conditions: Cleft Lip and Palate, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: The design of this study is a randomized control trial, double-blinded. Patients who meet criteria and consent will be randomized to receive LB or standard bupivacaine., primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: TRIPLE, maskingDescription: Surgeons and patients will be unaware of which cohort the subject will be randomized to be part of. The pharmacist, anesthesiologist, and research coordinator may all be aware of which drug is administered., whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: Liposomal Bupivacaine, interventions name: Bupivacain, interventions name: Epinephrine, outcomesModule primaryOutcomes measure: Visual Analog Pain Scores, primaryOutcomes measure: Opioid Use, primaryOutcomes measure: PROMIS Pediatric Mobility Questionnaire, eligibilityModule sex: ALL, minimumAge: 6 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06284421, orgStudyIdInfo id: IRB23-1068, briefTitle: Durometer for Measuring Uterine Tone, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-08, primaryCompletionDateStruct date: 2024-06-30, completionDateStruct date: 2024-09-30, studyFirstPostDateStruct date: 2024-02-29, lastUpdatePostDateStruct date: 2024-03-01, sponsorCollaboratorsModule leadSponsor name: University of Chicago, class: OTHER, descriptionModule briefSummary: This study will evaluate the use of a durometer to measure uterine tone in parturients undergoing cesarean delivery., conditionsModule conditions: Uterine Tone Disorders, conditions: Cesarean Section Complications, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: DEVICE_FEASIBILITY, maskingInfo masking: NONE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: Shore durometer, outcomesModule primaryOutcomes measure: feasibility of a durometer, secondaryOutcomes measure: durometer reading, secondaryOutcomes measure: durometer reading, secondaryOutcomes measure: durometer reading, secondaryOutcomes measure: correlation of durometer reading with a 0-10 uterine tone rating score (0= "no tone"; 10= "excellent tone"), secondaryOutcomes measure: correlation of durometer reading with a 0-10 uterine tone rating score (0= "no tone"; 10= "excellent tone"), secondaryOutcomes measure: correlation of durometer reading with a 0-10 uterine tone rating score (0= "no tone"; 10= "excellent tone"), eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 50 Years, stdAges: ADULT, contactsLocationsModule locations facility: University of Chicago, status: RECRUITING, city: Chicago, state: Illinois, zip: 60637, country: United States, contacts name: Naida M Cole, MD, role: CONTACT, phone: 773-702-6700, email: nmcole@bsd.uchicago.edu, contacts name: Somayeh Mohammadi, role: CONTACT, phone: 17738343274, email: mohammadis@bsd.uchicago.edu, geoPoint lat: 41.85003, lon: -87.65005, hasResults: False
protocolSection identificationModule nctId: NCT06284395, orgStudyIdInfo id: HGM1471-002/24, briefTitle: Two Schemes Response in Multiple Myeloma, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-11-20, primaryCompletionDateStruct date: 2024-03-20, completionDateStruct date: 2024-03-30, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: Hospital General de Mexico, class: OTHER_GOV, descriptionModule briefSummary: Retrospective study based on medical records of patients with multiple myeloma, eligible for stem cell transplantation, who received, first-line, the VTD or TD combination., conditionsModule conditions: Response, Acute Phase, conditions: Survivorship, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 83, type: ESTIMATED, armsInterventionsModule interventions name: Bortezomib, outcomesModule primaryOutcomes measure: Favorable Response, primaryOutcomes measure: Time to next treatment, secondaryOutcomes measure: Overall survival, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 90 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Hospital General de Mexico Dr. Eduardo Liceaga, status: RECRUITING, city: Mexico City, state: Cdmx, zip: 06720, country: Mexico, contacts name: Christian O Ramos Peñafiel, PhD, role: CONTACT, phone: 5523351588, email: leukemiachop33@gmail.com, contacts name: Adan G Gallardo Rodriguez, role: CONTACT, phone: +525584005072, email: nutriologo.agallardo8@gmail.com, contacts name: Juan M Cano Calderón, MD, role: SUB_INVESTIGATOR, contacts name: Juan F Zazueta Pozos, MD, role: SUB_INVESTIGATOR, contacts name: Adán G Gallardo Rodriguez, PhD, role: SUB_INVESTIGATOR, contacts name: Carlos Martínez Murillo, PhD, role: SUB_INVESTIGATOR, contacts name: Irma Olarte Carrillo, PhD, role: SUB_INVESTIGATOR, contacts name: Adolfo Martínez Tovar, PhD, role: SUB_INVESTIGATOR, contacts name: Christian O Ramos Peñafiel, PhD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 19.42847, lon: -99.12766, hasResults: False
protocolSection identificationModule nctId: NCT06284382, orgStudyIdInfo id: 2022-A02736-37, briefTitle: Interaction Between Early Trauma and Odor-induced Dopamine Release, acronym: T-ODOR, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-01, primaryCompletionDateStruct date: 2026-06-01, completionDateStruct date: 2027-06-01, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: Hôpital le Vinatier, class: OTHER, descriptionModule briefSummary: This prospective, double-blind, parallel-group controlled trial aims to investigate the consequence of early trauma on dopamine release evoked by positive valence odors., conditionsModule conditions: Trauma, Psychological, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: This is a prospective, single-center, double-blind, parallel-group controlled trial with two arms., primaryPurpose: BASIC_SCIENCE, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: High score at Childhood Trauma Questionnaire., interventions name: Low score at Childhood Trauma Questionnaire., outcomesModule primaryOutcomes measure: Dopamine transmission measured with positron emission tomography, secondaryOutcomes measure: Odor hedonic appreciation., secondaryOutcomes measure: Functional brain connectivity., secondaryOutcomes measure: Effective brain connectivity, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 30 Years, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06284369, orgStudyIdInfo id: Mongolia, briefTitle: Video Messages for Smoking Cessation Campaign, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2025-03, completionDateStruct date: 2025-04, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-03-04, sponsorCollaboratorsModule leadSponsor name: Loma Linda University, class: OTHER, descriptionModule briefSummary: 240 adult smokers will be recruited. Subjects will be asked to view video messages that encourage smoking cessation. The effect of these videos will be assessed., conditionsModule conditions: Smoking Cessation, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: SINGLE, maskingDescription: Participants don't know which video each subject is randomized to, whoMasked: PARTICIPANT, enrollmentInfo count: 240, type: ESTIMATED, armsInterventionsModule interventions name: Developing, Evaluating and Testing Video Messages for a Smoking Cessation Campaign, interventions name: Health Message Framing, outcomesModule primaryOutcomes measure: Message Engagement, secondaryOutcomes measure: Readiness to Quit Smoking, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 64 Years, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06284356, orgStudyIdInfo id: IRB Session 2022/14 Protocol 6, briefTitle: Pan Immune Inflammation Value for Perioperative Complications of Laparoscopic Sleeve Gastrectomy, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-05-01, primaryCompletionDateStruct date: 2023-05-01, completionDateStruct date: 2023-05-01, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-03-01, sponsorCollaboratorsModule leadSponsor name: Kahramanmaras Sutcu Imam University, class: OTHER, collaborators name: Elazig Special Eastern Anatolian Hospital, descriptionModule briefSummary: Morbid obesity emerges as a problem that causes serious complications and increased mortality rates. The most effective treatment for morbid obesity today is surgical treatment. The most preferred type of surgery in morbid obesity surgery in Turkey and around the world is Laparoscopic Sleeve Gastrectomy (LSG).While postoperative complications are divided into early and late complications, complications that develop during surgery and in the postoperative period before discharge are defined as perioperative complications. Early surgical complications after LSG include complications such as staple line bleeding, leaks, pulmonary thromboembolism, and torsion of the remnant stomach. It is important to detect these complications, which can be controlled with early intervention in the perioperative period.Monitoring blood parameters and monitoring inflammation are methods that are easily accessible and provide rapid evaluation. Platelet lymphocyte ratio (PLR) and neutrophil-lymphocyte ratio (NLR), which are used in the evaluation and detection of postoperative complications, have shed light on studies in this direction. Pan immune inflammation value (PIV) is calculated from blood parameters and has been used to evaluate prognosis and chemotherapy results in colorectal cancer.In this study, the diagnostic importance of changes in NLR, PLR, and PIV values in the preoperative and postoperative periods will be investigated in detecting complications that develop in the perioperative period before discharge in patients who underwent LSG., conditionsModule conditions: Morbid Obesity, conditions: Laparoscopic Sleeve Gastrectomy, conditions: Post Operative Complicaiton, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 159, type: ACTUAL, armsInterventionsModule interventions name: Laparoscopic Sleeve Gastrectomy, outcomesModule primaryOutcomes measure: Complication prediction after LSG with complete blood cell parameters, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Kahramanmaras SIU, city: Kahramanmaraş, zip: 46000, country: Turkey, geoPoint lat: 37.5847, lon: 36.92641, hasResults: False
protocolSection identificationModule nctId: NCT06284330, orgStudyIdInfo id: STU-2023-0881, briefTitle: CHARGE Study: CHoice ARchitecture Genetic tEsting, acronym: CHARGE, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-16, primaryCompletionDateStruct date: 2025-03, completionDateStruct date: 2025-08, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-04-05, sponsorCollaboratorsModule leadSponsor name: University of Texas Southwestern Medical Center, class: OTHER, descriptionModule briefSummary: CHARGE is a hybrid type I feasibility study to compare a choice architecture intervention for cascade genetic testing to usual care., conditionsModule conditions: Hereditary Cancer, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: HEALTH_SERVICES_RESEARCH, maskingInfo masking: NONE, enrollmentInfo count: 260, type: ESTIMATED, armsInterventionsModule interventions name: Enhanced cascade testing, outcomesModule primaryOutcomes measure: Rate of cascade genetic testing, secondaryOutcomes measure: Change in probands' family communication about genetic test results as measured by Proband survey, secondaryOutcomes measure: Proband's and relative's satisfaction with decision about participating in study measured at approximately 4- 7 months, secondaryOutcomes measure: Family functioning as reported by probands and relatives measured by Cancer Family Impact Scale, secondaryOutcomes measure: Proband's reaction to intervention materials as measured by proband survey., eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: UT Southwestern Medical Center, status: RECRUITING, city: Dallas, state: Texas, zip: 75390, country: United States, contacts name: Sukh Makhnoon, PhD, MS, role: CONTACT, phone: 214-648-3242, email: Chargestudy@utsouthwestern.edu, contacts name: Sukh Makhnoon, PhD, MS, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 32.78306, lon: -96.80667, hasResults: False
protocolSection identificationModule nctId: NCT06284304, orgStudyIdInfo id: N22DES, briefTitle: A Pilot Study of Dose dE-eScalaTion IN prostATe radIOtherapy usiNg the MRL, acronym: DESTINATION, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-29, primaryCompletionDateStruct date: 2025-04-01, completionDateStruct date: 2027-04-01, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-03-05, sponsorCollaboratorsModule leadSponsor name: The Netherlands Cancer Institute, class: OTHER, descriptionModule briefSummary: Trial design: A single centre phase II non-randomised studyTrial population: Men with intermediate risk localised prostate cancerRecruitment target: 20 patients in totalTrial objectives:* Primary To develop a 5 fraction de-escalated dose SBRT protocol capable of reducing side effects* Secondary  * To assess levels of acute GU and GI toxicity (CTCAE)  * To assess levels of late GU and GI toxicity (CTCAE)  * To assess late sexual quality of life (expanded EPIC, IIEF-5)  * To assess biochemical relapse-free survival at 2 yearsTrial treatment: All radiotherapy will be delivered on the MR-linac. Intraprostatic dose will be varied according to risk of local recurrence, based on mpMRI, PSA and histology. The whole prostate will receive 30 Gy in 5 fractions and the GTV plus intra-prostatic margin will receive an isotoxic 45 Gy prescription., conditionsModule conditions: Prostate Cancer, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: De-escalated radiotherapy, outcomesModule primaryOutcomes measure: Technical feasibility of treating prostate cancer with toxicity minimising radiotherapy on a MR-linac, secondaryOutcomes measure: Acute GU toxicity, secondaryOutcomes measure: Acute GI toxicity, secondaryOutcomes measure: Late GU toxicity, secondaryOutcomes measure: Late GI toxicity, secondaryOutcomes measure: PROMs, secondaryOutcomes measure: Biochemical free survival, eligibilityModule sex: MALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Netherlands Cancer Institute, status: RECRUITING, city: Amsterdam, zip: 1066CX, country: Netherlands, contacts name: Floris Pos, MD PhD, role: CONTACT, phone: +31 20 512 9111, email: f.pos@nki.nl, geoPoint lat: 52.37403, lon: 4.88969, hasResults: False